SCIENTISTS will today unveil results from the first large-scale human trial into a vaccine for nicotine which could see people immunised against addictions to smoking within the next five years.
A Swiss pharmaceutical company will reveal the outcome of a six-month vaccine trial of 300 volunteers, all of whom were heavy smokers before receiving injections to counter the habit.
Addiction experts said last night that the closely-guarded results, which are to be set out at the American Society of Clinical Oncology’s annual meeting in Orlando, Florida, were likely to be positive and could prove a watershed in the quest to introduce a nicotine vaccine.
